These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 36647169)

  • 21. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.
    Friedlaender A; Naidoo J; Banna GL; Metro G; Forde P; Addeo A
    Cancer Treat Rev; 2022 Mar; 104():102350. PubMed ID: 35093800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
    Guo H; Bai R; Cui J
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):101-110. PubMed ID: 32093454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
    Rizvi N; Ademuyiwa FO; Cao ZA; Chen HX; Ferris RL; Goldberg SB; Hellmann MD; Mehra R; Rhee I; Park JC; Kluger H; Tawbi H; Sullivan RJ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
    Tarhini AA; Eads JR; Moore KN; Tatard-Leitman V; Wright J; Forde PM; Ferris RL
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35973745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of immunotherapy in localized muscle invasive urothelial cancer.
    Kaur J; Choi W; Geynisman DM; Plimack ER; Ghatalia P
    Ther Adv Med Oncol; 2021; 13():17588359211045858. PubMed ID: 34567274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
    Peng Y; Li Z; Fu Y; Pan Y; Zeng Y; Liu J; Xiao C; Zhang Y; Su Y; Li G; Wu F
    Front Oncol; 2023; 13():1011810. PubMed ID: 36761954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
    de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tackling the immunotherapy conundrum: advances and challenges for operable non-small-cell lung cancer treatment.
    Attieh F; Chartouni A; Boutros M; Mouawad A; Kourie HR
    Immunotherapy; 2023 Nov; 15(16):1415-1428. PubMed ID: 37671552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review.
    Mukherjee S; Parmar K; Smyth E
    Ther Adv Med Oncol; 2022; 14():17588359221139625. PubMed ID: 36479471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review.
    Gatteschi L; Iannopollo M; Gonfiotti A
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.
    Pradhan M; Chocry M; Gibbons DL; Sepesi B; Cascone T
    Transl Lung Cancer Res; 2021 Jan; 10(1):590-606. PubMed ID: 33569339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
    Mamdani H; Matosevic S; Khalid AB; Durm G; Jalal SI
    Front Immunol; 2022; 13():823618. PubMed ID: 35222404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment.
    Glode AE; May MB
    Am J Health Syst Pharm; 2021 Apr; 78(9):769-780. PubMed ID: 33580648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Santopietro AL; Einstein D; Bellmunt J
    Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors.
    Yang H; Sun B; Ma W; Fan L; Xu K; Jia Y; Xu J; Wang Z; Yao F
    EBioMedicine; 2022 Oct; 84():104265. PubMed ID: 36116212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
    Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.